Using systematic reviews to identify research gaps - a case study: mIBG for the treatment of neuroblastoma in children by unknown
POSTER PRESENTATION Open Access
Using systematic reviews to identify research
gaps - a case study: mIBG for the treatment of
neuroblastoma in children
Jayne Wilson1*, Jenny Gains3, Veronica Moroz1, Mark Gaze3, Keith Wheatley2
From 2nd Clinical Trials Methodology Conference: Methodology Matters
Edinburgh, UK. 18-19 November 2013
Most childhood cancers are rare conditions, so research
needs to be efficient. With only a limited number of
children available for trials per year it seems sensible to
use data from previous research. Systematic review
methodology can do this whilst minimizing bias. Others
also recommend undertaking a systematic review as part
of a trial planning process in order to “reduce unwanted
duplication, help ensure that new research builds on
lessons from earlier research and place the findings of
the new research in proper context”. [Clark M 2007]
However, there are some who would question the value
of undertaking systematic reviews when only less than
optimally designed studies are available, which is
particularly true in paediatric oncology where non-
comparative studies dominate.
Using a recently completed systematic review that inves-
tigated the effectiveness of 131I-meta iodobenzylguanidine
(131I-mIBG) molecular radiotherapy for neuroblastoma,
we aim to present some of the methodological challenges
that we encountered during the review, such as study
identification, quality assessment and “salami” publica-
tions. We will also discuss the presentation, analysis and
interpretation of the results. We chose to perform quanti-
tative analyses, which gave estimates of effect sizes, with
measures of uncertainty, and evidence on dose/response
relationships. We considered that such analyses gave
greater insight into the data as a whole, while also being
aware that quantitative analyses of generally poor quality
data might be seen as providing a false sense of validity to
sub-optimally designed studies.
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